Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alpha Tau Medical Ltd. Warrant (DRTSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: DRTSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -48.61% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.99 | 52 Weeks Range 0.09 - 0.50 | Updated Date 06/6/2025 |
52 Weeks Range 0.09 - 0.50 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.17% | Return on Equity (TTM) -47.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 47275829 |
Shares Outstanding - | Shares Floating 47275829 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Alpha Tau Medical Ltd. Warrant
Company Overview
History and Background
Alpha Tau Medical Ltd. is a medical device company founded in 2009, specializing in brachytherapy for solid tumors. Their core technology, Alpha DaRT, delivers alpha radiation directly to tumors.
Core Business Areas
- Alpha DaRT Development: Focused on the research, development, and commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology.
Leadership and Structure
The company is led by a management team with experience in medical device development and commercialization. Details of the organizational structure are available in company filings.
Top Products and Market Share
Key Offerings
- Alpha DaRT: Alpha DaRT is the company's main product, a brachytherapy technology for treating solid tumors by delivering short-range alpha radiation. The market share is still emerging as the product gains regulatory approval and commercial traction. Competitors include established radiation therapy methods like external beam radiation and other brachytherapy techniques.
Market Dynamics
Industry Overview
The radiation oncology market is growing, driven by an aging population and increased cancer incidence. Advances in technology, such as targeted radiation therapies, are also contributing to market growth.
Positioning
Alpha Tau Medical Ltd. is positioned as an innovator in the brachytherapy market, offering a unique approach to cancer treatment with Alpha DaRT.
Total Addressable Market (TAM)
The global radiation oncology market is projected to reach billions of dollars. Alpha Tau Medical Ltd. aims to capture a portion of this market with its targeted alpha radiation therapy.
Upturn SWOT Analysis
Strengths
- Novel Alpha DaRT technology
- Targeted cancer treatment approach
- Potential for fewer side effects compared to traditional radiation therapy
Weaknesses
- Limited commercialization experience
- Reliance on Alpha DaRT for revenue
- Requires significant capital for development and expansion
Opportunities
- Expanding clinical applications of Alpha DaRT
- Securing regulatory approvals in key markets
- Partnering with hospitals and oncology centers
Threats
- Competition from established radiation therapy methods
- Technological advancements in alternative cancer treatments
- Regulatory hurdles and reimbursement challenges
Competitors and Market Share
Key Competitors
- Varian Medical Systems (VAR)
- Elekta (EKTAY)
Competitive Landscape
Alpha Tau Medical Ltd. competes with established players in the radiation oncology market, offering a novel approach to targeted alpha radiation therapy. The company's competitive advantage lies in the potential for Alpha DaRT to deliver effective treatment with fewer side effects.
Growth Trajectory and Initiatives
Historical Growth: As a developing company, Alpha Tau Medical Ltd.'s historical growth is characterized by research, development, and clinical trials of Alpha DaRT.
Future Projections: Future growth is dependent on securing regulatory approvals, expanding clinical use of Alpha DaRT, and achieving commercial success.
Recent Initiatives: Recent initiatives include ongoing clinical trials, regulatory submissions, and partnerships to expand market access.
Summary
Alpha Tau Medical Ltd. Warrant is a developing medical device company with a novel technology for targeted cancer treatment. The company's success depends on securing regulatory approvals, expanding clinical use of Alpha DaRT, and navigating the competitive landscape of the radiation oncology market. While the technology holds promise, the company faces challenges related to commercialization, competition, and regulatory hurdles. Continued execution and positive clinical results are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Tau Medical Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-08 | CEO & Chairman Mr. Uzi Sofer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 125 | Website https://www.alphatau.com |
Full time employees 125 | Website https://www.alphatau.com | ||
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.